Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

OQC raises £260m in Europe's biggest quantum round

3 min read
16:30UTC

Oxford Quantum Circuits closed a £260m Series C on 2 June led by Bullhound Capital, with the British Business Bank co-investing beside a macro hedge fund, an oil major and Spanish and Japanese sovereign funds.

TechnologyDeveloping
Key takeaway

British quantum now raises growth capital from commercial investors, with the state co-investing rather than underwriting.

Oxford Quantum Circuits (OQC) raised a £260m ($350m) Series C on Tuesday 2 June, the largest private quantum funding round Europe has recorded. Growth investor Bullhound Capital led. The British Business Bank (BBB), the UK's state development bank, joined the cap table as a co-investor, and chief executive Gerald Mullally called the raise a coming-of-age moment for British quantum.⁠1

A Series C is a company's third major institutional round, the stage at which a firm scales a proven product rather than proving one. Alongside Oxford backers Magdalen College and Oxford Science Enterprises sit macro hedge fund Rokos Capital Management, Spain's state finance arm COFIDES, Chevron Technology Ventures, and Japan's SBI and UTEC. Rokos and Chevron do not write deep-tech research cheques; their presence reads as commercial capital betting on near-term returns.

Britain put £2bn behind quantum in March 2026 through the ProQure procurement programme, the first country to commit at that scale. The BBB had already cornerstoned Quantum Motion's $160m Series C in May, taking the anchor position other investors follow. OQC is the first British quantum company to raise this size from a predominantly commercial group, with the state present yet not carrying the round.

Fault-tolerant systems, machines that correct their own errors well enough to run long computations, need fabrication capacity, and OQC already operates across the UK, United States, Japan and Spain. DSIT has not said whether the £260m funds British plant and jobs or expansion across those overseas sites, the question that decides what the £2bn quantum commitment actually buys at home.

Deep Analysis

In plain English

Quantum computers work differently from ordinary computers. Instead of processing information as 1s and 0s, they use quantum bits (qubits) that can be in multiple states simultaneously, making certain types of calculation far faster. OQC's approach uses a design called the coaxmon, developed at Oxford, which keeps qubits stable by engineering out interference that would otherwise scramble results. The £260m raised this week funds more qubits, better error correction, and the manufacturing capacity to sell access to those systems commercially. Why do investors care? Because industries from drug discovery to supply-chain optimisation to cryptography need calculations that classical computers would take thousands of years to complete. The race is to build a system reliable enough to run those calculations without errors.

Deep Analysis
Root Causes

Three converging forces made this round possible in June 2026 rather than two years earlier.

First, the UK government's £2bn ProQure procurement commitment in March 2026 converted hypothetical future state demand into a contracted revenue pipeline, giving crossover investors (Rokos Capital, Chevron Technology Ventures) a floor on OQC's addressable market.

Second, the British Business Bank's expanded £6.6bn direct-mandate, active from April 2026, put a state co-investor on the cap table without requiring OQC to structure the round as a grant or loan, removing the dilution friction that had historically pushed UK deep-tech founders toward US-dominated syndicates.

Third, OQC already operated commercially in the UK, US, Japan and Spain before this round, meaning the £260m is expansion capital for a revenue-generating business, not pre-revenue research funding.

What could happen next?
  • Opportunity

    UK quantum software companies now have a domestically-accessible hardware provider at commercial scale, reducing dependence on IBM or IonQ cloud access.

    Medium term · Assessed
  • Risk

    If OQC's fabrication investment goes to its existing Spanish or Japanese sites rather than UK facilities, the domestic manufacturing case for the ProQure strategy weakens.

    Short term · Assessed
  • Precedent

    Rokos Capital and Chevron as quantum investors establishes a crossover-capital playbook that other UK quantum companies (Quantum Motion, PsiQuantum UK) can reference when approaching non-specialist investors.

    Medium term · Reported
First Reported In

Update #7 · OQC's £260m sets European quantum record

Oxford Quantum Circuits· 7 Jun 2026
Read original →
Causes and effects
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.